375 related articles for article (PubMed ID: 28092474)
1. Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).
Simões-Pires CA; Bertrand P; Cuendet M
Expert Opin Ther Pat; 2017 Mar; 27(3):229-236. PubMed ID: 28092474
[TBL] [Abstract][Full Text] [Related]
2. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
Qin HT; Li HQ; Liu F
Expert Opin Ther Pat; 2017 May; 27(5):621-636. PubMed ID: 28033734
[TBL] [Abstract][Full Text] [Related]
3. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
4. Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications.
Thaler F
Pharm Pat Anal; 2012 Mar; 1(1):75-90. PubMed ID: 24236715
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.
De Vreese R; D'hooghe M
Eur J Med Chem; 2017 Jul; 135():174-195. PubMed ID: 28453994
[TBL] [Abstract][Full Text] [Related]
6. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY
Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106
[TBL] [Abstract][Full Text] [Related]
7. Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.
Smil DV; Manku S; Chantigny YA; Leit S; Wahhab A; Yan TP; Fournel M; Maroun C; Li Z; Lemieux AM; Nicolescu A; Rahil J; Lefebvre S; Panetta A; Besterman JM; Déziel R
Bioorg Med Chem Lett; 2009 Feb; 19(3):688-92. PubMed ID: 19111466
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
Tashima T; Murata H; Kodama H
Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors.
Zhang Y; Feng J; Liu C; Fang H; Xu W
Bioorg Med Chem; 2011 Aug; 19(15):4437-44. PubMed ID: 21733698
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present).
Zhao C; Dong H; Xu Q; Zhang Y
Expert Opin Ther Pat; 2020 Apr; 30(4):263-274. PubMed ID: 32008402
[No Abstract] [Full Text] [Related]
11. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
[TBL] [Abstract][Full Text] [Related]
12. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
[TBL] [Abstract][Full Text] [Related]
13. Discovery of the First Irreversible HDAC6 Isoform Selective Inhibitor with Potent Anti-Multiple Myeloma Activity.
Liu F; Liu C; Chai Q; Zhao C; Meng H; Xue X; Yao TP; Zhang Y
J Med Chem; 2023 Jul; 66(14):10080-10091. PubMed ID: 37463038
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of thienopyrimidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.
Wang J; Su M; Li T; Gao A; Yang W; Sheng L; Zang Y; Li J; Liu H
Eur J Med Chem; 2017 Mar; 128():293-299. PubMed ID: 28213282
[TBL] [Abstract][Full Text] [Related]
15. Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells.
Rosik L; Niegisch G; Fischer U; Jung M; Schulz WA; Hoffmann MJ
Cancer Biol Ther; 2014 Jun; 15(6):742-57. PubMed ID: 24618845
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
Pinho BR; Reis SD; Guedes-Dias P; Leitão-Rocha A; Quintas C; Valentão P; Andrade PB; Santos MM; Oliveira JM
Pharmacol Res; 2016 Jan; 103():328-39. PubMed ID: 26657418
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
Senger J; Melesina J; Marek M; Romier C; Oehme I; Witt O; Sippl W; Jung M
J Med Chem; 2016 Feb; 59(4):1545-55. PubMed ID: 26653328
[TBL] [Abstract][Full Text] [Related]
18. Development and therapeutic impact of HDAC6-selective inhibitors.
Dallavalle S; Pisano C; Zunino F
Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
[TBL] [Abstract][Full Text] [Related]
19. Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects.
Vishwakarma S; Iyer LR; Muley M; Singh PK; Shastry A; Saxena A; Kulathingal J; Vijaykanth G; Raghul J; Rajesh N; Rathinasamy S; Kachhadia V; Kilambi N; Rajgopal S; Balasubramanian G; Narayanan S
Int Immunopharmacol; 2013 May; 16(1):72-8. PubMed ID: 23541634
[TBL] [Abstract][Full Text] [Related]
20. Selective Inhibitors of Histone Deacetylase 10 (HDAC-10).
Pojani E; Barlocco D
Curr Med Chem; 2022; 29(13):2306-2321. PubMed ID: 34468295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
